Biocryst Pharmaceuticals Inc SEC filings BCRX
Biocryst Pharmaceuticals Inc has 1,000 filings in SEC EDGAR's recent list, going back to Mar 8, 2016. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 18, 2025 | — |
| CORRESP | Letter to the SEC | Dec 16, 2025 | — |
| 425 | Filing | Dec 3, 2025 | — |
| 425 | Filing | Oct 14, 2025 | — |
| 425 | Filing | Oct 14, 2025 | — |
| 425 | Filing | Oct 14, 2025 | — |
| 425 | Filing | Oct 14, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 18, 2022 | — |
| CORRESP | Letter to the SEC | Jan 14, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 22, 2021 | — |
| EFFECT | Filing | May 14, 2020 | — |
| CORRESP | Letter to the SEC | May 12, 2020 | — |
| CORRESP | Letter to the SEC | May 4, 2020 | — |
| CT ORDER | Filing | May 1, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2020 | — |
| CT ORDER | Filing | Dec 17, 2018 | — |
| 425 | Filing | Jun 21, 2018 | — |
| 425 | Filing | Jun 21, 2018 | — |
| 425 | Filing | Jun 11, 2018 | — |
| 425 | Filing | Jun 11, 2018 | — |
| 425 | Filing | Jun 7, 2018 | — |
| 425 | Filing | Jun 7, 2018 | — |
| 425 | Filing | Jun 7, 2018 | — |
| CT ORDER | Filing | Jun 6, 2018 | — |
| 425 | Filing | Jun 5, 2018 | — |
| 425 | Filing | May 9, 2018 | — |
| 425 | Form 425 for biocryst pharmaceuticals inc | May 8, 2018 | — |
| 425 | Form 425 for biocryst pharmaceuticals inc | May 8, 2018 | — |
| 425 | Filing | Apr 10, 2018 | — |
| 425 | Filing | Apr 10, 2018 | — |
| CT ORDER | Filing | Apr 6, 2018 | — |
| 425 | Filing | Apr 2, 2018 | — |
| 425 | Filing | Apr 2, 2018 | — |
| 425 | Filing | Apr 2, 2018 | — |
| 425 | Filing | Apr 2, 2018 | — |
| 425 | Filing | Mar 22, 2018 | — |
| 425 | Filing | Mar 22, 2018 | — |
| 425 | Filing | Mar 8, 2018 | — |
| 425 | Filing | Mar 7, 2018 | — |
| 425 | Filing | Feb 28, 2018 | — |
| 425 | Filing | Feb 27, 2018 | — |
| 425 | Filing | Feb 27, 2018 | — |
| 425 | Filing | Feb 27, 2018 | — |
| 425 | Filing | Feb 27, 2018 | — |
| 425 | Filing | Feb 27, 2018 | — |
| 425 | Filing | Feb 27, 2018 | — |
| 425 | Filing | Feb 23, 2018 | — |
| 425 | Form 425 for biocryst pharmaceuticals inc | Feb 22, 2018 | — |
| 425 | Filing | Feb 22, 2018 | — |
| 425 | Filing | Feb 22, 2018 | — |
| 425 | Filing | Feb 20, 2018 | — |
| 425 | Filing | Jan 23, 2018 | — |
| 425 | Filing | Jan 22, 2018 | — |
| 425 | Filing | Jan 22, 2018 | — |
| 425 | Filing | Jan 22, 2018 | — |
| 425 | Filing | Jan 22, 2018 | — |
| 425 | Filing | Jan 22, 2018 | — |
| 425 | 8-k | Jan 22, 2018 | — |
| EFFECT | Filing | Dec 12, 2017 | — |
| CORRESP | Letter to the SEC | Dec 8, 2017 | — |
| EFFECT | Filing | Jun 12, 2017 | — |
| CORRESP | Letter to the SEC | Jun 8, 2017 | — |
| UPLOAD | Letter from the SEC | May 17, 2017 | — |
| CT ORDER | Filing | Mar 3, 2017 | — |
| CT ORDER | Filing | Dec 28, 2016 | — |
| CT ORDER | Filing | Sep 14, 2016 | — |
| CT ORDER | Filing | Jul 26, 2016 | — |
| CT ORDER | Filing | Jun 9, 2016 | — |
| EFFECT | Filing | Apr 18, 2016 | — |
| CORRESP | Letter to the SEC | Apr 14, 2016 | — |
Showing 71 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 882796
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.